324 related articles for article (PubMed ID: 15905321)
1. Increased bone adiposity and peroxisomal proliferator-activated receptor-gamma2 expression in type I diabetic mice.
Botolin S; Faugere MC; Malluche H; Orth M; Meyer R; McCabe LR
Endocrinology; 2005 Aug; 146(8):3622-31. PubMed ID: 15905321
[TBL] [Abstract][Full Text] [Related]
2. CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption.
Motyl KJ; Raetz M; Tekalur SA; Schwartz RC; McCabe LR
Am J Physiol Regul Integr Comp Physiol; 2011 May; 300(5):R1250-60. PubMed ID: 21346244
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss.
Botolin S; McCabe LR
J Cell Physiol; 2006 Dec; 209(3):967-76. PubMed ID: 16972249
[TBL] [Abstract][Full Text] [Related]
4. Caspase-2 deficiency protects mice from diabetes-induced marrow adiposity.
Coe LM; Lippner D; Perez GI; McCabe LR
J Cell Biochem; 2011 Sep; 112(9):2403-11. PubMed ID: 21538476
[TBL] [Abstract][Full Text] [Related]
5. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
Lazarenko OP; Rzonca SO; Suva LJ; Lecka-Czernik B
Bone; 2006 Jan; 38(1):74-84. PubMed ID: 16137931
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral delivery of PPARγ shRNA alters the balance of osteogenesis and adipogenesis, improving bone microarchitecture.
James AW; Shen J; Khadarian K; Pang S; Chung G; Goyal R; Asatrian G; Velasco O; Kim J; Zhang X; Ting K; Soo C
Tissue Eng Part A; 2014 Oct; 20(19-20):2699-710. PubMed ID: 24785569
[TBL] [Abstract][Full Text] [Related]
7. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice.
Botolin S; McCabe LR
Endocrinology; 2007 Jan; 148(1):198-205. PubMed ID: 17053023
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of the receptor for activation of NF-kappaB and decreased runt-related transcription factor 2 expression in bone of rats with streptozotocin-induced diabetes.
Hie M; Tsukamoto I
Int J Mol Med; 2010 Oct; 26(4):611-8. PubMed ID: 20818503
[TBL] [Abstract][Full Text] [Related]
9. Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function.
Hamann C; Goettsch C; Mettelsiefen J; Henkenjohann V; Rauner M; Hempel U; Bernhardt R; Fratzl-Zelman N; Roschger P; Rammelt S; Günther KP; Hofbauer LC
Am J Physiol Endocrinol Metab; 2011 Dec; 301(6):E1220-8. PubMed ID: 21900121
[TBL] [Abstract][Full Text] [Related]
10. Normal bone density obtained in the absence of insulin receptor expression in bone.
Irwin R; Lin HV; Motyl KJ; McCabe LR
Endocrinology; 2006 Dec; 147(12):5760-7. PubMed ID: 16973725
[TBL] [Abstract][Full Text] [Related]
11. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways.
Botolin S; McCabe LR
J Cell Biochem; 2006 Oct; 99(2):411-24. PubMed ID: 16619259
[TBL] [Abstract][Full Text] [Related]
12. Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation.
Hie M; Iitsuka N; Otsuka T; Tsukamoto I
Int J Mol Med; 2011 Sep; 28(3):455-62. PubMed ID: 21567076
[TBL] [Abstract][Full Text] [Related]
13. Increased cathepsin K and tartrate-resistant acid phosphatase expression in bone of streptozotocin-induced diabetic rats.
Hie M; Shimono M; Fujii K; Tsukamoto I
Bone; 2007 Dec; 41(6):1045-50. PubMed ID: 17916452
[TBL] [Abstract][Full Text] [Related]
14. Protein Phosphatase PP5 Controls Bone Mass and the Negative Effects of Rosiglitazone on Bone through Reciprocal Regulation of PPARγ (Peroxisome Proliferator-activated Receptor γ) and RUNX2 (Runt-related Transcription Factor 2).
Stechschulte LA; Ge C; Hinds TD; Sanchez ER; Franceschi RT; Lecka-Czernik B
J Biol Chem; 2016 Nov; 291(47):24475-24486. PubMed ID: 27687725
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.
Vidal-Puig AJ; Considine RV; Jimenez-Liñan M; Werman A; Pories WJ; Caro JF; Flier JS
J Clin Invest; 1997 May; 99(10):2416-22. PubMed ID: 9153284
[TBL] [Abstract][Full Text] [Related]
16. Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
Ito Y; Yamamoto M; Furukawa S; Fukui M; Morishita K; Kitao T; Shirahase H
Biol Pharm Bull; 2021; 44(5):659-668. PubMed ID: 33952822
[TBL] [Abstract][Full Text] [Related]
17. Effects of angiotensin-converting enzyme inhibitor, captopril, on bone of mice with streptozotocin-induced type 1 diabetes.
Diao TY; Pan H; Gu SS; Chen X; Zhang FY; Wong MS; Zhang Y
J Bone Miner Metab; 2014 May; 32(3):261-70. PubMed ID: 23934056
[TBL] [Abstract][Full Text] [Related]
18. Antidiabetic and Antihyperlipidemic Properties of a Triterpenoid Compound, Dehydroeburicoic Acid, from Antrodia camphorata in Vitro and in Streptozotocin-Induced Mice.
Kuo YH; Lin CH; Shih CC
J Agric Food Chem; 2015 Nov; 63(46):10140-51. PubMed ID: 26503742
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
Ali AA; Weinstein RS; Stewart SA; Parfitt AM; Manolagas SC; Jilka RL
Endocrinology; 2005 Mar; 146(3):1226-35. PubMed ID: 15591153
[TBL] [Abstract][Full Text] [Related]
20. Transgenic overexpression of tartrate-resistant acid phosphatase is associated with induction of osteoblast gene expression and increased cortical bone mineral content and density.
Gradin P; Hollberg K; Cassady AI; Lång P; Andersson G
Cells Tissues Organs; 2012; 196(1):68-81. PubMed ID: 22248481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
